Form 4: Boundless Bio Executive Acquires Stock Options
SEC Filing Form 4
Neil Abdollahian, Chief Business Officer of Boundless Bio, Inc., reports the acquisition of stock options.
Summary
- Neil Abdollahian, Chief Business Officer of Boundless Bio, Inc., filed a Form 4 with the SEC.
- The filing reports the acquisition of 23,191 stock options on March 27, 2024.
- The stock options have an exercise price of $16.
- The options vest in 48 substantially equal monthly installments beginning on April 27, 2024, and expire on March 26, 2034.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's confidence in the company's future prospects.
Stakeholder Impact
- The acquisition of stock options by a company executive can be viewed positively by shareholders as it aligns management's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 03/27/2024 | Date of transaction: acquisition of stock options |
| 04/27/2024 | Vesting start date for the stock options |
| 03/26/2034 | Expiration date of the stock options |
| 03/29/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.